NCT07141771 - An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

December 31, 2030

Conditions

SCLC, Extensive Stage

Interventions

DRUG

Serplulimab

Serplulimab: 4.5mg/kg, ivgtt, 21 days/cycle

DRUG

Fluzoparib

100mg BID oral

DRUG

Topotecan/Irinotecan/Paclitaxel/Temozolomide

second-line chemotherapy options: Topotecan/Irinotecan/Paclitaxel/Temozolomide etc.

DRUG

Etoposide/Carboplatin/Cisplatin

First-line chemotherapy: the original first-line chemotherapy regimen, recommended Etoposide 100mg / m2 d1-3, Carboplatin AUC = 5 d1 / Cisplatin 75mg / m2 d1 q21d

DRUG

Lurbinectedin

2.6mg/m2 (3 patients, if safe, in the 3.2mg / m2 dose group) or 3.2 mg / m2, ivgttd,21d / cycle .

DRUG

Temozolomide

150mg/m2, oral, on days 1-5,28d / cycle

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER